CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for EQRx Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

EQRx Inc
50 Hampshire Street
Phone: (617) 315-2255p:617 315-2255 CAMBRIDGE, MA  02139  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 11/9/2023.
This company ceased filing statements with the SEC on 11/20/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
EQRx, Inc. is a pharmaceutical company. The Company is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The Company brands include EQRx and Remaking Medicine. The Company's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Co-Founder Alexis A.Borisy 51 12/1/2021 8/1/2019
President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Director Melanie I.Nallicheri 54 3/31/2023 1/1/2020
General Counsel, Corporate Secretary DinaCiarimboli 54 2/1/2022 2/1/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
CMLT
CMLTU
EQRX

General Information
Number of Employees: 362 (As of 12/31/2022)
Outstanding Shares: 487,696,181 (As of 10/27/2023)
Shareholders: 108
Stock Exchange: NASD
Federal Tax Id: 861691173
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024